Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 81.15B |
| Revenue (ttm) | 44.07B |
| Net Income (ttm) | 5.01B |
| Shares Out | n/a |
| EPS (ttm) | 2.47 |
| PE Ratio | 16.19 |
| Forward PE | 7.20 |
| Dividend | 2.26 (5.68%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 2,297 |
| Average Volume | 2,329 |
| Open | 39.97 |
| Previous Close | 40.00 |
| Day's Range | 39.75 - 40.18 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | 0.39 |
| RSI | 32.71 |
| Earnings Date | Jul 31, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; l...
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts t...
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July. Und...
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug
Cignaaccused BristolMyers Squibb of violating antitrust law by keeping generic versions of its blood cancerdrug Pomalyst off the market to retain a monopoly.
Cigna files antitrust case against Bristol Myers over Pomalyst sales
Bristol Myers Squibb Announces Dividend
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. ...
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Ph...
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader at EHA 2025
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being...
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Bristol Myers Squibb (NYSE:BMY) today announced positive data from the pivotal Phase 3 POETYK PsA-1 trial (IM011-054) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with act...
Notable healthcare headlines for the week: Bristol Myers Squibb, Novo Nordisk and Sanofi in focus
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped
Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet
Bristol Myers' is making a big move into next-generation cancer treatments. But there's still more to prove.
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash.
Watch CNBC's full interview with Bristol Myers CEO Christopher Boerner
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2095975132-53d951c567e846e5b977bfb95efda524.jpg)
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration
U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co . (NYSE: BMY) entered into a co-development and co-commercialization agreement . The pact focuses on BioNTech’s investigational bispecific an...
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda
Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus
Why the stock rally fizzled plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.